Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Plus Pembrolizumab in Advanced Solid Tumors and NSCLC
NCT02963610Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Started Mar 2017; status: terminated.
02
Drugs
lenalidomide
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02963610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963610.